FDA Master Protocol In Metastatic Breast Cancer Likely In The Works
This article was originally published in The Pink Sheet Daily
Oct. 21 public workshop cosponsored by prominent oncology groups will discuss international genomically driven trial to test multiple agents in metastatic breast cancer.
You may also be interested in...
FDA wants data standards in place so the increasingly popular clinical research collaborations can continue growing, but a researcher states that government also could make funding available to sustain the consortia.
Sponsors say the large number of biomarkers that will be searched for in candidates for the lung cancer trial should allow researchers to find patients much faster, and will offer cost-savings over traditional drug development.
I-SPY 2 investigators are buoyed by “strong signal” for neratinib in high-risk subgroup in adaptive design study. Investors, however, are underwhelmed by results.